Infinitt, SmartPACS sign agreement for joint venture

TriMed Staff | | Health Imaging | Screening
SmartPACS and Infinitt Co. Ltd., who developed a professional partnership in 2000, signed a memorandum of understanding this week that is a prelude to a joint venture agreement to be signed by the end of 2005.
   
Both companies develop, provide, and market PACS and 3D systems for the medical imaging market.
   
The joint venture will help SmartPACS and Infinitt to grow their business, the companies said. Within the memorandum of understanding, the companies established action dates and timelines, as well as business and marketing plans. A board of directors was also formulated.

TriMed Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.